Inactive Instrument

QSAM Biosciences, Inc.

Equities

QSAM

US74738N2027

Biotechnology & Medical Research

Q2Earth, Inc. Announces Resignation of David Shields as the Company’S Chief Financial Officer

January 23, 2019 at 04:30 pm EST

Q2Earth, Inc. announced that January 18, 2019 was the final day of service of David Shields as the Company’s Chief Financial Officer, who had previously tendered his resignation. Mr. Shields and the Company had no disagreements that led to his resignation. Mr. Shields left to pursue other professional opportunities not competitive with the Company.

Latest news about QSAM Biosciences, Inc.

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	May. 02	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	Nov. 13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	23-09-28	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	23-06-14	CI
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23-05-23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	23-04-26	CI
QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer	23-04-05	CI
QSAM Biosciences, Inc. announced that it has received $3 million in funding	23-03-30	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
QSAM Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of Cyclosam(R) Targeting Metastatic Bone Cancer	23-03-08	CI
QSAM Biosciences, Inc. Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	23-02-28	CI
QSAM Biosciences, Inc. Recruits the Ellis Fischel Cancer Center At the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam for Bone Cancer	23-02-22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
QSAM Biosciences, Inc Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer	22-10-26	CI
QSAM Biosciences, Inc. announced a financing transaction	22-09-29	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam	22-07-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
QSAM Biosciences, Inc. Announces the First Patient Commenced Treatment in Its Clinical Trial Evaluating Cyclosam® in Patients with Metastatic Bone Cancer	22-04-28	CI
QSAM Biosciences Inc. Receives Japanese Patent for Its Clinical Stage Radiopharmaceutical Drug Candidate, Cyclosam	22-04-12	CI

Chart QSAM Biosciences, Inc.

Duration

Period

More charts

Company Profile

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Companyâs technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+34.92%	38.48B
CELLTRION, INC.	-12.11%	26.22B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B

Other Biotechnology & Medical Research